Glenmark Pharmaceuticals under a licensing agreement with Denmark-based Pharma Medico has launched Nourkrin Woman, a globally renowned, clinically-proven proteoglycan replacement formula, for normalizing hair growth cycle.
Nourkrin Woman will be exclusively marketed in India by Glenmark. The product contains Marilex, a proprietary scientific formula, rich in specific proteoglycans (PG) essential for hair follicle development, which helps in normalizing, supporting and maintaining the Hair Growth Cycle.
The company stated that it is a proven formula, based on more than 56 scientific studies and is recognized by leading regulatory agencies globally. Nourkrin is the number one product in UK and Europe for hair loss management and is available in more than 40 countries worldwide.
According to Sujesh Vasudevan, President and Head – India, Middle East and Africa - Glenmark the company has been present in the field of Dermatology for over 4 decades bringing globally advanced therapies to Indian patients. The launch of Nourkrin will enable millions of women in India manage hair loss not by just preventing hair loss but by normalizing the hair growth cycle and tackling the problem at the follicular level.
“It is alarming to note that 60% women experience hair loss at some stage in their lives and in India there are more than 90 million women reported to have hair loss. With male and female hair loss patterns being different, Nourkrin Woman is the first and exclusive product focusing on female hair loss problem through proteoglycan replacement, said Rajesh Kapur, Senior Vice President – Sales & Marketing, Glenmark.
The core prescription product will be promoted exclusively to dermatologists across the country. It will also be available at select retail chemists and healthcare portals.
According to Indian Journal of Clinical and Experimental Dermatology, 15.3% women in India reportedly suffer from hair loss. As per 2011 Census data, population of women in the country was 586.47 million. This means 90 million women have hair loss problem.
Number of factors such as stress, pollution, certain medical disorders, childbirth, conditions caused by hormonal imbalances, use of certain drugs, nutritional deficiencies, and use of styling products disrupt the hair growth cycle and lead to hair loss in women. Nourkrin Woman addresses the core issue of normalizing the hair growth cycle.
Nourkrin Woman, available as tablets, is an easy-to-use therapy compared to clinical procedures and hair sprays and creams. The tablets have to be consumed twice a day for six months.
Nourkrin Woman will be exclusively marketed in India by Glenmark. The product contains Marilex, a proprietary scientific formula, rich in specific proteoglycans (PG) essential for hair follicle development, which helps in normalizing, supporting and maintaining the Hair Growth Cycle.
The company stated that it is a proven formula, based on more than 56 scientific studies and is recognized by leading regulatory agencies globally. Nourkrin is the number one product in UK and Europe for hair loss management and is available in more than 40 countries worldwide.
According to Sujesh Vasudevan, President and Head – India, Middle East and Africa - Glenmark the company has been present in the field of Dermatology for over 4 decades bringing globally advanced therapies to Indian patients. The launch of Nourkrin will enable millions of women in India manage hair loss not by just preventing hair loss but by normalizing the hair growth cycle and tackling the problem at the follicular level.
“It is alarming to note that 60% women experience hair loss at some stage in their lives and in India there are more than 90 million women reported to have hair loss. With male and female hair loss patterns being different, Nourkrin Woman is the first and exclusive product focusing on female hair loss problem through proteoglycan replacement, said Rajesh Kapur, Senior Vice President – Sales & Marketing, Glenmark.
The core prescription product will be promoted exclusively to dermatologists across the country. It will also be available at select retail chemists and healthcare portals.
According to Indian Journal of Clinical and Experimental Dermatology, 15.3% women in India reportedly suffer from hair loss. As per 2011 Census data, population of women in the country was 586.47 million. This means 90 million women have hair loss problem.
Number of factors such as stress, pollution, certain medical disorders, childbirth, conditions caused by hormonal imbalances, use of certain drugs, nutritional deficiencies, and use of styling products disrupt the hair growth cycle and lead to hair loss in women. Nourkrin Woman addresses the core issue of normalizing the hair growth cycle.
Nourkrin Woman, available as tablets, is an easy-to-use therapy compared to clinical procedures and hair sprays and creams. The tablets have to be consumed twice a day for six months.